Acknowledgement

This activity is provided by Talem Health and RME Collaborative.
     
Supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see
https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS educational requirements issued by the US Food and Drug Administration.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Nursing Contact Hour
• Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team. 

Program Overview

The opioid epidemic is a national health crisis that results in tens of thousands of opioid-related overdose deaths annually. It is critical that the millions of patients with pain receive appropriate care while mitigating the risks of opioid misuse, abuse, and diversion. This CME/CE activity, which is Part 3 of a three-part series titled Tackling the Opioid Crisis: Strategies to Improve Best Practices and Patient Outcomes, will review fundamental elements of addiction and evidence-based strategies for recognizing and treating opioid use disorder. Best practices for counseling patients and caregivers about safe opioid use, storage, and disposal will also be discussed.

This activity meets most states’ requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement issued by the FDA in September 2018.

Learning Objectives

Upon completion of this activity, participants should be better able to: 

• Utilize appropriate methods for monitoring patients using opioid therapy
• Counsel patients about the safe use of opioids, safe disposal, potential for abuse and dependence, and overdose prevention (use of naloxone)

Faculty

Michael J. Brennan, MD
Medical Director, Pain Center of Fairfield
Fairfield, CT
Senior Attending Physician, Department of Medicine, Physical Medicine, and Rehabilitation
Bridgeport Hospital
Bridgeport, CT


Jeffrey A. Gudin, MD
Professor of Anesthesiology, Perioperative Medicine, and Pain Management
University of Miami, Miller School of Medicine 
Miami, FL

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-23-019-H08-P)
Type of Activity: Application

For Pharmacists: Upon successfully completing the post-test with a score of 67% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Michael J. Brennan, MD, has disclosed the following relevant financial relationships: speakers’ bureau for SCILEX Pharmaceuticals, Inc.

Jeffrey A. Gudin, MD, has disclosed the following relevant financial relationships: consultant for Collegium Pharmaceutical, Inc., Hisamitsu Pharmaceutical Co., Inc., Quest Diagnostics, and Sanofi; and grant/research support and stock ownership interest in Virpax Pharmaceuticals.

Planners, Managers, and Reviewers

Barbara P. Yawn, MD, MSc, FAAFP, has disclosed the following relevant financial relationships: consultant for Teva Pharmaceuticals.

Gabriela Pankow, RN, has no relevant financial relationships to disclose.

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

General Questions
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.